Breaking News

Samsung Invests in Generate: Biomedicines

Aims to advance AI-driven protein therapeutics discovery.

Author Image

By: Charlie Sternberg

Associate Editor

The Samsung Life Science Fund has invested in Generate: Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and worth KRW 240 billion, the fund also invested in BrickBio earlier this year.   Generate, founded by Flagship Pioneering, is a US-based clinical-stage company leading in generative biology. The company applies AI-based optimization and de novo generation to discover and design novel protein therapeutics, and has a rob...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters